Exercise Versus Corticosteroid Randomized Clinical Trial for Plantar Fasciitis
A Clinical Trial of a Multi-Element Exercise Program for Plantar Fasciopathy in Workers Required to Stand for Prolonged Periods of Time
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1T3
- University of British Columbia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult workers (men and women) between the ages of 19 and 60
- Workers required to stand for 6 hours or more in their respective workplaces
- Diagnosed with plantar fasciopathy (plantar fasciitis). All diagnoses will be made by a physiotherapist based on the presentation of palpable pain at or around the plantar medial heel, in addition to pain during weight-bearing activities and the presence of morning pain.
- Only individuals with pain for longer than 12 months will be included.
Exclusion Criteria:
- A history of surgery to their plantar fascia
- Osteoarthritis or other degenerative musculoskeletal disorders affecting the lower extremity
- Individuals who have received corticosteroid injections into their affected plantar fascia at any time in the past will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Exercise
Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
|
lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
Walking along a straight line on the ground, for 5 sets of 30 strides
The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended.
The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
The foot is placed sideways at the edge of a step.
After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each.
Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot.
The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch.
Same procedure is then repeated for the left foot.
|
|
Active Comparator: Standard of Care
This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
|
This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each.
Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
A 22-gauge, 1.5" needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine.
Prior to injection, the skin will be sterilized with povidone-iodine.
The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Foot and Ankle Disability Index (FADI) at 6 weeks
Time Frame: 6 weeks
|
Patient-centered health-realted quality of life indicator measuriing disability at the foot and ankle.
|
6 weeks
|
|
Change from Baseline in Foot and Ankle Disability Index (FADI) at 12 weeks
Time Frame: 12 weeks
|
Patient-centered health-realted quality of life indicator measuriing disability at the foot and ankle.
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Ultrasound-Based Grading of Pathology at 12 weeks
Time Frame: 12 weeks
|
A 3-level ordinal scale assessing a composite of hypoechogenicity and neovascularity will be documented.
|
12 weeks
|
|
Change in Acoustoelastographic Analysis of Plantar Fascia Elasticity at 12 Weeks
Time Frame: 12 weeks
|
A novel method of calculating the mechanical properties of deformation dependent soft-tissue using only ultrasound cine-images.
Specific outcomes will include plantar fascial stiffness, strain, and modulus of elasticity.
|
12 weeks
|
|
Change in Visual Analog Scale for Pain at 12 weeks
Time Frame: 12 weeks
|
Participants mark on a 100mm line the amount of pain on average they have experienced over the past 7 days.
Items for both pain at work and pain with activities of daily living are included.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jack Taunton, Dr., University of British Columbia
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Foot Diseases
- Musculoskeletal Diseases
- Fasciitis
- Fasciitis, Plantar
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
Other Study ID Numbers
- H10-03368
- RS2010-IG20 (Other Grant/Funding Number: WorkSafeBC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.